AbbVie
ABBV
#32
Rank
NZ$641.58 B
Marketcap
NZ$363.14
Share price
-1.20%
Change (1 day)
17.31%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2026 (TTM): NZ$3.51

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$3.50. In 2025 the company made an earnings per share (EPS) of NZ$4.07 a decrease over its 2024 EPS that were of NZ$4.13.

EPS history for AbbVie from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$3.51-13.88%
2025NZ$4.07-1.26%
2024NZ$4.13-11.86%
2023NZ$4.68-58.95%
2022NZ$11.412.49%
2021NZ$11.13121.58%
2020NZ$5.02-44.7%
2019NZ$9.0845.84%
2018NZ$6.239.72%
2017NZ$5.68-9.54%
2016NZ$6.2716.28%
2015NZ$5.40184.1%
2014NZ$1.90-57.15%
2013NZ$4.43

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.23-36.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$48.09 1,272.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$24.67 604.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$15.93 354.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$11.67 233.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.07 73.12%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$11.84 237.97%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$6.62 88.99%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$11.43 226.30%๐Ÿ‡บ๐Ÿ‡ธ USA